Premium
Nucleus‐Targeted Organoiridium–Albumin Conjugate for Photodynamic Cancer Therapy
Author(s) -
Zhang Pingyu,
Huang Huaiyi,
Banerjee Samya,
Clarkson Guy J.,
Ge Chen,
Imberti Cinzia,
Sadler Peter J.
Publication year - 2019
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201813002
Subject(s) - photosensitizer , human serum albumin , photodynamic therapy , cytotoxicity , chemistry , conjugate , cancer cell , biophysics , albumin , serum albumin , phototoxicity , phosphorescence , maleimide , in vitro , cancer research , cancer , photochemistry , fluorescence , biochemistry , medicine , biology , polymer chemistry , organic chemistry , quantum mechanics , mathematical analysis , mathematics , physics
An organoiridium–albumin bioconjugate ( Ir1‐HSA ) was synthesized by reaction of a pendant maleimide ligand with human serum albumin. The phosphorescence of Ir1‐HSA was enhanced significantly compared to parent complex Ir1 . The long phosphorescence lifetime and high 1 O 2 quantum yield of Ir1‐HSA are highly favorable properties for photodynamic therapy. Ir1‐HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC 50 ; 0.8–5 μ m , photo‐cytotoxicity index PI=40–60), while remaining non‐toxic to normal cells and normal cell spheroids, even after photo‐irradiation. This nucleus‐targeting organoiridium‐albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom